1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients
1-Month DAPT After Current-Generation DES PCI May Be Best for High-Bleeding-Risk Patients...
Read More
European Heart Journal 2026
European Heart Journal 2026 Optimal Potassium Range in Heart Failure: 4.2–5.0 mmol/L *...
June 11, 2026
ACC/AHA 2026
ACC/AHA 2026 First-Ever Guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome A...
June 11, 2026
June 11, 2026
A multicenter European study with prominent participation and first authorship by a Jordanian investigator.
A multicenter European study with prominent participation and first authorship by a...
June 7, 2026
Safer NSAID Choice for AF Patients Receiving DOACs
Safer NSAID Choice for AF Patients Receiving DOACs Source: JAMA, June 3, 2026. TCTMD...
June 7, 2026
Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for Oral Anticoagulation
Single Versus Dual Antiplatelet Therapy After TAVR in Patients Without an Indication for...
June 7, 2026
NEJM / EAS 2026 – Heart-2 Trial
NEJM / EAS 2026 – Heart-2 Trial VERVE-102, a one-time IV therapy designed to permanently...
June 7, 2026
EAS 2026 Highlights: During the ongoing EAS Congress 2026 in Athens
EAS 2026 Highlights: During the ongoing EAS Congress 2026 in Athens (May 24–27,...
June 2, 2026
Can Tirofiban Improve 90-Day Outcomes After Poor Response to Stroke Thrombolysis?
Can Tirofiban Improve 90-Day Outcomes After Poor Response to Stroke Thrombolysis? New...
June 2, 2026
A new RNA-based Therapy (microRNA) Change Post-MI Remodeling?
A new RNA-based Therapy (microRNA) Change Post-MI Remodeling? Phase 2 HF-REVERT trial...
June 2, 2026
ESC Heart Failure 2026 (Barcelona | May 17–20, 2026):
ESC Heart Failure 2026 (Barcelona | May 17–20, 2026): Cardiac Glycosides Making a Comeback...
June 2, 2026